Browsing Tag
RayThera
1 post
Biogen is paying up to $1bn for preclinical optionality. What does RayThera really add?
Biogen's $1 billion RayThera deal expands its immunology pipeline and raises fresh capital allocation questions. Read what BIIB investors should watch next.